Tocilizumab BS MA
Tocilizumab biosimilar developed by Mochida Pharmaceutical. Reference product Actemra (RoActemra in the European Union).
About Tocilizumab BS MA
Tocilizumab BS MA is Mochida's tocilizumab, the second approved in Japan, in March 2026, in both infusion and under-the-skin forms. Mochida has not named the developer.
Status by market
United States
Not listed by FDA.
European Union
Not listed by EMA.
United Kingdom
Not listed by MHRA.
Japan · Tocilizumab BS MA
Pharmaceuticals and Medical Devices Agency and MHLWApprovedCanada
Not listed by HC.
India
Not listed by CDSCO.
United Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Tocilizumab BS MA holds an approval, these are the other tocilizumab biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| PMDA | 1 | Celltrion (Avtozma) |
Same developer, other molecules
Other biosimilars in the Atlas developed by Mochida Pharmaceutical: Adalimumab BS MA, Etanercept BS MA, Pegfilgrastim BS Mochida / Nipro, Teriparatide BS Mochida.
Chronology
- PMDAMar 2026Approved by MHLW
Sources
S020PMDA, list of approved biosimilar products in Japan (as of July 2026) Primary (regulator)
Planning tocilizumab biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant